Ophthalmology
Vitreous Floaters
1
Pipeline Programs↗
0
Active Trials↗
1
Companies Involved↗
Vitreous floaters is an early-stage landscape with 1 program across 1 company. The most active players are Fresenius Kabi Oncology Ltd.. 1 therapy is approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved1
Analysis
Trial Status
2
clinical trials
Unknown status2 · 100%
Clinical Trials
Trial Activity
Low Dose Atropine for Symptomatic Vitreous Floaters
Unknown status·—·Phase 2·NCT06174935·200 enrolled
Comparison the Topical Anesthesia and Retrobulbar Anesthesia for 27-gauge Vitrectomy for Vitreous Floaters
Unknown status·—·N/A·NCT03049163·30 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)